Loading…
Ken GriffinAdded
Citadel Advisors · Q2 2026
$5.31M
297.86K shares · 0.0% of portfolio
Caris Life Sciences, Inc.
Caris Life Sciences, Inc. (CAI) is listed on NASDAQ and classified in Biotechnology, part of the Healthcare sector. It is headquartered in Irving, United States and has 1,846 employees. The company is worth $8.96B and trades at 19.1x its earnings of the last twelve months; the median for its sector is 24.3x. Revenue was $812.03M in fiscal 2025, up 97.0% from the year before. It reported a net loss of $68.09M. The share price is 4.3% below its 52-week high of $33.13. 7 of the 38 superinvestors we track held it at the end of Q2 2026. The largest position belongs to Philippe Laffont (Coatue Management), at $174.99M. In that quarter, 3 of them opened or added to the position. No open-market insider trades in it were filed over the last 30 days.
Written from the data on this page: SEC filings (13F, Form 4, annual reports) and market prices.
Year by year, from the annual reports; dividends from the payments themselves.
Bars are year-end balances; lines are what happened during the year.
Major managers that reported this stock in their latest 13F.
▲ +14.4% over 5Y.
This stock has less than 5 years of price history — the answer would measure a shorter period than the one asked for.
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
Seven formulas applied to the reported numbers, each with its assumption next to the result. None of them predicts a price.
Square root of 22.5 × earnings × book value. Blind to intangibles, so it undervalues software and brands.
This formula has no meaning here — usually a loss, negative cash flow, or a missing input.
Median P/E of 24.3 among peers in the sector.
This formula has no meaning here — usually a loss, negative cash flow, or a missing input.
Cash flow growing 5.0% a year for 10 years, discounted at 10%, then 2.5% forever.
Sector median of 14.1x operating profit, less net debt. Banks have no EBITDA.
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| TWSTTwist Bioscience Corp | $135.47 | — | 19.0x | 0.00% | -29.59% | $8.98B |
| PTGXProtagonist Therapeutics, Inc | $139.53 | 134.2x | 10.7x | 0.00% | 10.98% | $9.03B |
| HNGEHinge Health, Inc. | $109.93 | 36.3x | 25.6x | 0.00% | 30.38% | $8.87B |
| TXG10x Genomics, Inc. | $69.75 |
This formula has no meaning here — usually a loss, negative cash flow, or a missing input.
The average of the method families that answered, not of the seven numbers: four of the seven start from the same earnings per share.
4 methods answered, across 3 families.
Room for errors in the reported numbers.
-63.4% from the average.
Models, not forecasts, and not investment advice. How each formula works →
| — |
| 11.0x |
| 0.00% |
| -9.40% |
| $9.09B |
| KYMRKymera Therapeutics, Inc. | $110.85 | — | 6.1x | 0.00% | -24.15% | $9.12B |
| IBRXImmunityBio, Inc. | $8.31 | — | — | 0.00% | — | $8.81B |